News Contact Us

Zelda Therapeutics partners with German medical cannabis group

Author : Sunil Hebbalkar | Published Date : 2018-09-04 

Australian bio-pharmaceutical company, Zelda Therapeutics Ltd. has reportedly announced a collaboration with the German medicinal cannabis group HAPA Medical. As per trusted reports, the collaboration would offer HAPA first rights for manufacturing and distributing  Zelda’s clinically validated formulations in the expanding Germany market.

An official press release by Zelda claims that HAPA is an early mover to the Germany medical cannabis market and is reportedly developing a vertically integrated business including pharmaceutical manufacturing, medical outreach, cultivation, patient education and distribution to medical clinics and pharmacies across Germany.

Dr. Richard Hopkins, MD at Zelda Therapeutics was reportedly quoted stating that the collaboration would effectively extend the global reach of Zelda’s relationships and would further demonstrate its focus on commercializing the company’s clinically validated formulations.

The move is crucial as Germany with a population of 83 million, is predicted to be the largest single medical cannabis market in the world, Hopkins added.

As per Ricardo Pendón, HAPA’s Managing Director, the firm is pleased with the collaboration with Zelda as it is recognized as one of the world’s leading science-driven medical cannabis companies. Attaining access to Zelda’s unique product portfolio would play a significant role in HAPA’s success in the future, claims Pendón.

Reportedly, Germany is an a rather lucrative ground for Zelda given that the regional government passed a legislation in March 2017, enabling clinicians to prescribe cannabis in certain circumstances. However, self-cultivation and recreational use of cannabis is still sternly prohibited in Germany, cite sources.

As per an official statement under the German regulatory framework, patients that are registered with their insurer will reportedly be offered full reimbursement on the cost of cannabis related medicines.

Sources on this matter also claim that the legally subsidized nature of the cannabis medicine industry in Germany has led to a catalyzed growth in the number of patients with figures that have far exceeded the initial predictions.

About Author

Sunil Hebbalkar

Sunil Hebbalkar

Sunil Hebbalkar currently works as a content writer for fractovia.org and other portals. A post graduate in mechanical design engineering, he nurtures a passion for writing articles related to myriad industry verticals such as the technology, automotive, and healthcare sectors. When free, Sunil pursues his interest in cycling, reading, and sketching. He can be contacted at- [email protected] | https://twitter.com/HSuniel

Related News

Titanium sponge: An overview of the material in terms of physical properties, grades, and applications

Published Date: 2019-02-26         Author: Sunil Hebbalkar

In recent decades, the increasing involvement of the scientific community in the development of material science and technologies has led to the introduction of innovative material alternatives. These alternatives have apparently been gaining considerable popularity among prominent industries such a... Read More

Entergy to build 100 MW solar energy plant in Mississippi Delta

Published Date: 2018-11-10         Author: Sunil Hebbalkar

U.S. based energy company, Entergy Mississippi, Inc. has signed a deal with a Canadian energy company to construct solar energy farm of 100 MW capacity. This will be one of the largest utility-owned solar energy firms in the state. The Mississippi Public Service Commission hasn’t provided sanc... Read More

Roche steps up cost cuts via efficiency to stay ahead of opponents

Published Date: 2018-09-15         Author: Sunil Hebbalkar

Roche, the biggest manufacturer of cancer medications across the world, has reportedly started an efficiency drive in a bid to counterattack competition by employing cost cuts. According to sources familiar with the development, Roche is struggling with sales as its biotech product portfolio ages am... Read More

© 2019 Fractovia. All Rights Reserved